Equity Profile

WST

West Pharmaceutical Services, Inc.

Health CareLife Sciences Tools & Services$23.4B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

West Pharmaceutical Services, Inc. (WST) is a leading provider of innovative solutions for the pharmaceutical and biotechnology industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and will indicate how well West has managed its costs and revenues this quarter.

N/A

Revenue Growth

Revenue growth will provide insights into demand for West's products and overall market performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

West Pharmaceutical Services, Inc. (WST) is a leading provider of innovative solutions for the pharmaceutical and biotechnology industries. The company specializes in the development and manufacturing of drug delivery systems and containment solutions, which are crucial for ensuring the safety and efficacy of medications. As a key player in the health care sector, West's performance can be influenced by trends in drug development and regulatory changes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1-2026, West reported an EPS of $2.13, surpassing estimates by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Focus on expanding product offerings in the drug delivery space.
Commitment to maintaining high-quality standards in manufacturing.
Plans to enhance operational efficiency to support growth.

Expectations

Wall Street Expectations

Overall, expectations are mixed as West has a strong track record of beating EPS estimates, but revenue figures remain uncertain. Investors will be keen to see if the company can maintain its growth trajectory.

Bull Case

If West continues its trend of beating EPS estimates, it could signal strong operational performance and increased market share, leading to a positive stock reaction.

Bear Case

Conversely, any signs of slowing revenue growth or increased costs could raise concerns about the company's ability to sustain profitability, resulting in a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and can it exceed the previous quarter's performance?

Given West's strong history of EPS surprises, this will be a key indicator of the company's financial health and operational efficiency.

What insights can management provide regarding revenue growth and market demand?

Understanding revenue trends will be crucial for assessing the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate West's ability to capitalize on new drug delivery technologies, which could drive higher-than-expected revenue growth.

Supporting Evidence

West has consistently beaten EPS estimates, suggesting strong operational capabilities.

Recent trends in the pharmaceutical industry indicate increased demand for innovative delivery solutions.

The options market is pricing in a larger move than historical averages, suggesting investor uncertainty.

Key Risk

If West's revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether West can maintain its growth momentum in a competitive landscape, making these metrics critical.

Bull Confirmed If

An EPS of $2.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating that investors expect volatility around the earnings report.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West beats expectations, history suggests the stock could rise by about 2.75%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see limited movement as investors reassess future growth.

Miss

A miss could lead to a decline of around 14.40%, as concerns about profitability and growth potential surface.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches in drug delivery systems.
2Insights into operational efficiencies and cost management strategies.
3Updates on market demand trends for pharmaceutical products.
4Management's outlook on future revenue growth and market opportunities.
5Discussion of competitive pressures and how West plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

West Pharmaceutical Services, Inc. (WST) is a leading provider of innovative solutions for the pharmaceutical and biotechnology industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and will indicate how well West has managed its costs and revenues this quarter.

N/A

Revenue Growth

Revenue growth will provide insights into demand for West's products and overall market performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1-2026, West reported an EPS of $2.13, surpassing estimates by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Focus on expanding product offerings in the drug delivery space.
Commitment to maintaining high-quality standards in manufacturing.
Plans to enhance operational efficiency to support growth.

Expectations

Wall Street Expectations

Bull Case

If West continues its trend of beating EPS estimates, it could signal strong operational performance and increased market share, leading to a positive stock reaction.

Bear Case

Conversely, any signs of slowing revenue growth or increased costs could raise concerns about the company's ability to sustain profitability, resulting in a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and can it exceed the previous quarter's performance?

Given West's strong history of EPS surprises, this will be a key indicator of the company's financial health and operational efficiency.

What insights can management provide regarding revenue growth and market demand?

Understanding revenue trends will be crucial for assessing the company's future prospects and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate West's ability to capitalize on new drug delivery technologies, which could drive higher-than-expected revenue growth.

Supporting Evidence

West has consistently beaten EPS estimates, suggesting strong operational capabilities.

Recent trends in the pharmaceutical industry indicate increased demand for innovative delivery solutions.

The options market is pricing in a larger move than historical averages, suggesting investor uncertainty.

Key Risk

If West's revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether West can maintain its growth momentum in a competitive landscape, making these metrics critical.

Bull Confirmed If

An EPS of $2.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating that investors expect volatility around the earnings report.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West beats expectations, history suggests the stock could rise by about 2.75%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see limited movement as investors reassess future growth.

Miss

A miss could lead to a decline of around 14.40%, as concerns about profitability and growth potential surface.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches in drug delivery systems.
2Insights into operational efficiencies and cost management strategies.
3Updates on market demand trends for pharmaceutical products.
4Management's outlook on future revenue growth and market opportunities.
5Discussion of competitive pressures and how West plans to address them.